StemCell Therapy

With more than 140 years of heritage to its name, the homegrown TCM brand is still breaking new ground in Singapore

Eu Yan Sang may have started off in Singapore with one clinic in 2002, but today, the brand has more than 20 traditional Chinese medicine (TCM) clinics islandwidea new addition at Chinatown Point recently opened in October 2019.

The brands clinics have three different concepts, each catering to a different need. The Eu Yan Sang TCM Clinic serves patients in the heartlands and aims to help with acute and chronic illnesses, while the Eu Yan Sang TCM Wellness Clinic helps patients with sub-health, skin as well as weight and pain management; it offers travel health solutions for busy executives, too. The Eu Yan Sang Premier TCM Centre is managed by a team of experienced physicians who are trained to manage complex or chronic health conditions through a combination of prescribed herbal medication, acupuncture, tui na and cupping.

(Related: Now A Century-Old, Eu Yan Sang Has Transformed Holistic Healthcare)

Eu Yan Sangs longevity can be credited to its balanced use of technology and tradition. While it prioritises a holistic health and wellness approach thats based on its centuries-old TCM heritage, Eu Yan Sang has simultaneously built a reputation for quality, safety and innovation.

We aim to demystify TCM for the modern patient through continuous learning and by upgrading and adapting our practices, which are supported by rigorous standards in terms of structures, processes and controls, explains Lim Swee Cheng, general manager (clinic services and operational excellence) at Eu Yan Sang.

See the rest here:
Technology and Tradition are at the Heart of Eu Yan Sang's Longevity - Singapore Tatler

Michael Cusumano agrees. Hes a professor at the Massachusetts Institute of Technology who spearheaded entrepreneurship and innovation initiatives at the Tokyo University of Science from 2016 to 2017, and lived and worked in Japan for eight years. Closing a company or selling it is also considered something of a failure and shame in Japan, and this feeling goes back centuries. So these cultural issues also seem to encourage families to keep firms going, he says. Japanese society, and the economy, is not as flexible as the US, and so Japan does not generate big new firms so easily. The tendency is to preserve what they have.

Yet shinise companies arent exempt from hardship. Kongo Gumi, a construction company founded back in 578, lasted a staggering 1,400 years before going into liquidation in 2006 due to debt. In the future, Matsuzaki believes that there will be benefits in combining the strengths of the two business models.

The key will be to foster more synergy between shinise companies and start-ups, she says. Shinise companies strength in resources, their reputation in the industry, [a] strong network. By mixing new technology and rapid decision-making with shinise, she thinks start-ups can become a lethal weapon for Japan's future.

Yet back at Tsuen Tea, current owner Tsuen has no such lofty goals. I was born here by chance. My ancestors continued the tea business and Im taking over, Tsuen says. My goal is not to make the company bigger or expand sales or go worldwide. Whats most important is to just continue this.

Additional reporting by Yoko Ishitani and Mari Murakami.

See more here:
Why so many of the world's oldest companies are in Japan - BBC News

Another way to support a healthy gut as we age, as well as a healthy brain, is getting your healthy fats. For Sinclair, who went through the '90s anti-fat fiasco, realizing he could still enjoy healthy fats was a breakthrough.

"I used to avoid fat like the plague because of recommendations from nutritionists. I would love to get my childhood back, to be able to eat that stuff. [Now] I eat cheese, and I eat yogurt. And I think I'm healthier than I ever was. But you can't eat the same quantity of cheese as you do plant food. You'd just gain too much weight."

And as far as his favorites, Sinclair says, "If I eat meat, I eat fish if I have a choice. And then I take my omega-3s.I always have a couple of avocados in the fridge or on the table. Avocado oil is fantastic for sure. And olive oil, I'm becoming more and more convinced is the thing to do, so I've always put liberal amounts on bread and on salads."

If you're serious about hacking your longevity, Sinclair is the guy to listen to. In the full podcast, he says we may eventually be calling aging a disease, but until then, including these foods in your daily rotation will help fuel your body and mind to feel your best.

See the original post:
This Is What A Harvard Geneticist Eats To Look & Feel 10 Years Younger - mindbodygreen.com

A pair of juniors and a pair of true freshmen pitchers will need to transition into starters quickly in order to fill the biggest holes in Cal Poly Baseballs roster.

Junior righthander Taylor Dollard and junior southpaw Andrew Alvarez bring experience to the weekend pitching ranks, while freshmen righthanders Drew Thorpe and Derek True will be jumping straight into the action in their first collegiate season.

Were thin, but weve got a good group of guys that work hard, pitching coach Jake Silverman said. Its going to take every single one of them for us to be successful this year

Cal Poly lost two All-Big West first team pitchers from last season. Friday starter Bobby Ay (9-1, 3.27 ERA) was a ninth round draft pick of the Arizona Diamondbacks while top reliever Michael Clark (6-3, 2.61 ERA, eight saves) graduated.

Dollard (5-0, 2.89 ERA, 4 saves) will take over as the Friday starter.

The last two years, [Dollards] just been a huge impact on this team, Alvarez said. Now, having him as a Friday starter, hes hopefully going to take the role of Bobby Ay and exceed that level.

Dollard was also an All-Big West first team selection following his successful sophomore season as a reliever. Cal Polys season opener against Connecticut on Friday, Feb. 14 will be his first collegiate start.

Ive been working really hard to become a starter, Dollard said. Its something Ive wanted since I stepped on campus.

Dollards most impressive performance came in Cal Polys final match of the season against UC Santa Barbara. In the Friday game, Dollard pitched two hitless innings and recorded four strikeouts. The next day, he pitched six innings in relief to continue the Mustangs hopes of reaching the postseason.

Dollard has had success out of the bullpen for his entire Cal Poly career. He earned three wins and three saves through 19 appearances as a freshman in the 2018 season. Last season, he improved to five wins and four saves through another 19 appearances.

When it comes to attitude and mentality, he has it, Silverman said. The biggest thing for him is learning the longevity of a season with 15 starts.

Alvarez (1-3, 5.10 ERA), who began the 2019 season as a reliever, will be the Saturday starter.

The junior southpaw will be completing his transition into a starting pitcher, which began last year. In the last six weeks of the 2019 season, Alvarez had six starts.

It was something I didnt really expect coming into my sophomore year, Alvarez said. Before, I was just a lefty specialist. One or two at bats a night. Then, I was facing multiple hitters, multiple innings. So its really allowed me to grow.

When transitioning from a reliever to a starter, the focus is on shifting the pitchers mindset to be focused on longevity, according to Silverman.

When youre a starter, youre going to take punches and youre going to take some hits, Silverman said. You gotta just keep working through those and pitching out of problems.

A pair of true freshman will round out the pitching lineup. Drew Thorpe, from Washington, Utah is expected to be the Sunday starter while Santa Barbara native Derek True will be the Tuesday opener.

Thorpe had a 7-1 record and a 1.93 ERA in his senior season at Desert Hills High School. A three-time All-Utah honoree, Thorpe said he was excited when head coach Larry Lee told him he would begin the season as a starter.

Its what Ive been working for since I got here, Thorpe said. As a freshman, thats pretty cool to come in and be one of the weekend guys.

Hes a guy that can eat up a lot of innings because he has the ability to get you out in multiple ways, Silverman said. Hes the type of guy that has some longevity with what hes going to do too.

True, also a righthander, had a perfect 9-0 season with a 2.20 ERA to close out his career at Santa Barbara High School.

Coming here to play for coach lee, its just an honor, True said. Not too many people can say that. Hes one of the best coaches in the country, if not the best. So having that opportunity was a no-doubter for me.

In his senior season, True was named the league MVP after recording 75 strikeouts over 57 1/3 innings. Silverman called True a really nice surprise.

Hes got a chance to throw really hard and have power stuff, Silverman said. He just has to learn how to wrangle that in He has the makings to be something special.

The Mustangs will begin its tough non-conference schedule at the MLB4 Tournament in Scottsdale, Ariz. from Feb. 14-16. After facing Connecticut Friday, Cal Poly will take on defending national champion Vanderbilt on Saturday and runner-up Michigan on Sunday.

The older guys, they have experience So theyve been battle tested, Silverman said. The younger guys, they just have to learn from it. theyre going to take the licks a little bit, but as long as they just take the experience that they get and use it day to day, itll be an incredible information gathering on their behalf to get better.

Read more here:
Baseball brings a new lineup of starting pitchers into the 2020 season - Mustang News

I am 62 and have only just reached the marmalade years (The preserve of a long life, G2, 10 February), but I hope your readers enjoy my marmalade poem:

I am turning into somebody elsesomebody who makes marmalade.

Somebody who rolls a cool thick Sevilleagainst her cheekbreathing in the smell of Spainin the dusk of Devon.

Somebody who cuts thin peelskimming golden frothfrom amber soupin a January kitchen.

When did this happen?Watching the teaspoon for the set,boiling the jarswriting tidy labels.

I should be wearinga white dressgazing up through blossomat a Spanish blue sky

biting into olive flesh,and running my fingersalong red wallswarm with secrets

instead of lining upnine jars of sun.

(First published in Exclamat!on Vol 1 and Moor Poets Vol IV)Helen ScaddingDartington, Devon

Clearly Im not yet in my marmalade years. I proudly took a jar my partner and I had made to my 90-year-old marmalade-producing dad as a gift on Saturday. On Sunday morning I got up to find him improving the jars contents by reboiling it in a saucepan. Later I found the gift back in its jar and in my bag ready to be taken home. Those born between the wars may well have the edge on marmalade producing. Im not so sure about manners. Jan StillawayLondon

My mother had her 100th birthday last summer, and we made marmalade together a couple of weeks ago when I visited her from France. We needed to as she consumes up to a jar a week, and my sister cant keep her supplied. I think that is evidence for marmalade contributing to longevity. That and sloe gin.Clare RonaldRiec sur Belon, France

Exactly 50 years ago, the song Reflections of my Life was a top 10 hit for the pop group Marmalade.Steve MooreLeumeah, New South Wales, Australia

Read more:
Get ready for the marmalade years - The Guardian

A kitchen by Annabode, featuring sleek white cabinets and countertops, and an island clad with rift-sawn white oak. Photo courtesy of Annabode

Designer Anna Smithperhaps youve spotted her coveted organic-modern interiors on her popular Instagram feed @annabodeshares what she expects (and hopes) to see in Colorado design this year. Get ready to take notes!

Is maximalism having a moment? What textures are trending this year? And is hygge here to stay? We put those questionsand moreto Anna Smith, founder and owner of Annabode & Co., a Denver-based design firm known for environmentally and socially responsible spaces that artfully marry irresistible organic textures with modern detailing. Here, she shares the trends and design details she and design partner Taryn Steil will be keeping an eye on in 2020.

5280 Home:What sources do you rely upon to stay abreast of design trends?Anna Smith: We believe in designing for longevity rather than for the moment.For inspiration, we especially love walking through Denvers historic neighborhoodsthere are so many interesting, inventive design details that you only notice up close!And we use Instagram to stay on top of what our favorite makers are creating.

What kinds of furniture forms would you like to see more of this year?Wed love to see more minimal interpretations of Victorian turned-wood furniture. There are a lot of designers playing with pared-down versions of Jenny Lind and Spanish Revival pieces that are just stunning.

And how about textures?Texture is our favorite element in any design.We are especially loving brick for floors, fireplaces, and backsplashesthe texture and color options are endless, and it can read anywhere from incredibly earthy to crisp and modern.

Are certain patterns gaining in popularity?Were seeing a lot of grid patternsthink: checks, squares, etc.

And how about hygge? Do you think the craze will continue?Hygge will always be in demand. Who doesnt like to be cozy and comfortable?

Have you noticed a shift from minimalism to maximalism among your clientele? And if so, what are they ready to go big with?We havent, but our firms philosophy attracts a certain type of client. We believe in owning what you need and what makes you happy, and in letting go of all the extra material baggage in your life.After all, the more you own, the more work it is to take care of it.

Whats a trend youd like to see take off in 2020?Wed like to see more companies becoming B Corps. Can that be trendy?

And one you hope will go away?Vinyl flooring.Terrible for you, terrible for the planet.

And finally, have you noticed a shift in what homeowners want, need, or value when it comes to home decor? Whats important to them now?I think homeowners are beginning to understand that where and how they shop has a bigger impact beyond just themselves and their homes. We help make sure that impact is a positive one.

Original post:
Anna Smith of Annabode's Style Picks and Predictions for 2020 - 5280 | The Denver Magazine

Image: portal of the mayor and government of Moscow Maxim Denisov

In February, for participants of the project Moscow longevity in five universities of the capital will begin classes in the new curriculum. This is stated on the portal of the mayor and government of Moscow.

During these sessions, the elderly do not learn a new profession, but gain knowledge, develop, communicate and find like-minded people. Now, after winter break, the participants of the project starts next school semester. Together with the programs of the past half-year for them to launch a new directions and courses, stated in the message.

In Lomonosov Moscow state University will host a series of lectures Philosophers of the eternal and the present, which focuses on topics such as happiness, meaning of life, morality, nature of man and his place in the world.

Moscow state art-industrial Academy named after Stroganov invites everyone to join the club of fans of cinema. In the classroom, the project participants will learn about all stages of development of domestic cinema.

At the State Institute of Russian language named after Pushkin work book club. The participants will discuss their favorite works of Russian writers of the XVIIIXXI centuries, as well as learn about the technique of reading at home, which can be used in the classroom with their grandchildren.

the Russian economic University named after Plekhanov earn interest clubs. During the course home Economics and interior design, which combines theoretical and practical parts, participants will create a design project of the premises in a special computer program. In the club Home and landscape design will tell you how to do the layout of the garden plot.

Moscows Polytechnic University, offers three new educational programs.

the press service of the Moscow Department of labour and social protection of population announced that all classes for participants of the program Moscow longevity is free.

As specified, in the mediumm one course lasts three to five months, lessons are held one to two times a week.

participation in the program Moscow longevity take more than 200 thousand people. Classes in the project are free and available in all parts of the city. In addition, to help the older generation the city authorities attract social workers and volunteers.

the Project Moscow longevity created at the initiative of the mayor of the capital in 2018. From 2019, he became a regular. Men from 60 years and women from 55 years old to attend classes in cultural centers, parks, schools, sports and recreational complexes and other organizations.

see also

members of the Moscow longevity has created a map of skating rinks and lignecasino Moscow longevity unable to join peoples militia

Originally posted here:
Universities have developed educational programs for members of the Moscow longevity - International Law Lawyer News

This report describes a study of the Longevity and Anti-senescence Therapy market for the evaluation period 2025. It also incorporates a Longevity and Anti-senescence Therapy market growth factor analysis comprising Porters five-factor analysis and supply chain analysis. A segmental breakdown of the market is added for a greater understanding of the market mechanism.

New Report onLongevity and Anti-senescence Therapy Market size | Industry Segment by Applications (Hospital, Medical Service Institution and Drug and Device Sales), by Type (Hemolytic Drug Therapy, Gene Therapy, Immunotherapy and Other Stem Cell Therapies), Regional Outlook, Market Demand, Latest Trends, Longevity and Anti-senescence Therapy Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report holds a granular analysis of the Longevity and Anti-senescence Therapy industry situations, market demands, the report provides in-depth Longevity and Anti-senescence Therapy market analysis and data according to classifications such as types, Application/end user, regional, company and competitive environment. A broad analysis has been done on Longevity and Anti-senescence Therapy market share of all the segments. The report also includes review of recent development in Longevity and Anti-senescence Therapy market. The report also explores detailed picture of growth drivers and inhibitors of the global Longevity and Anti-senescence Therapy market.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/77398

Report Scope:

The study includes the profiles of key players in the Longevity and Anti-senescence Therapy market with a significant global and/or regional presence. The Longevity and Anti-senescence Therapy market competition by top Manufacturers Covers:

Longevity and Anti-senescence Therapy Market Outlook by Applications:

Longevity and Anti-senescence Therapy Market Statistics by Types:

The Longevity and Anti-senescence Therapy Market report demonstrates growth trends and future opportunities at geographic level. This report helps in understanding the global Longevity and Anti-senescence Therapy Market trends in the industry and develop schemes to be executed in the future. Furthermore, the Longevity and Anti-senescence Therapy Market research report summarizes some of the leading enterprises in the Longevity and Anti-senescence Therapy industry. It mentions their strategic initiatives and offers a brief about their business.

The study on the global Longevity and Anti-senescence Therapy market includes qualitative factors such as drivers, restraints, and opportunities. The study covers the qualitative and quantitative analysis of the market segmented based on type, technology, and vertical. Moreover, the study provides similar information for the key geographies.

The Longevity and Anti-senescence Therapy Analysis report offers an entire substantial study of the Longevity and Anti-senescence Therapy market, key tactics followed by leading Longevity and Anti-senescence Therapy industry Players and impending segments. The previous and current Longevity and Anti-senescence Therapy industry forecast analysis in terms of volume and value along with research conclusions is a decisive part of Longevity and Anti-senescence Therapy market analysis report.

Objective of Studies of Longevity and Anti-senescence Therapy Market:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/77398

Excerpt from:
Longevity and Anti-senescence Therapy Market Analysis by Size, Share, Growth, Tr - News by aeresearch

A vast body of evidence demonstrates that exercising regularly offers a bulwark against life-threatening complications, such as heart disease. The case for exercise could not be clearer but when it comes to how much you need to do to extend your lifespan, the jury is often out. Research is increasingly shedding light on this area, however, and one study shows that even a little exercise can go a long way.

The NHS recommends adults should do at least 150 minutes (two hours and 30 minutes) of moderate-intensity aerobic activity, such as cycling or fast walking, every week to reap the health benefits.

While the more exercise you do the better, according to findings published in the British Journal of Sports Medicine, even partaking in 10 minutes of exercise a week a day can reduce your risk of developing life-threatening complications.

The study was based on data from more than 88,000 U.S. adults who participated in the National Health Interview Survey between 1997 and 2008. All of the participants were ages 40 to 85 and did not have any chronic diseases when they took the survey.

They also provided demographic and health information, and were tracked by researchers for about nine years.

READ MORE:How to live longer: This simple activity may increase your life expectancy

About 8,000 people died during the follow-up period, and the researchers found virtually any amount of exercise reduced the risk of dying of cardiovascular disease, cancer or any other cause.

What was particularly noteworthy is the study found participants who did just 10 to 59 minutes of light-to-moderate intensity physical activity each week had an 18 percent lower risk of early death than people who were sedentary.

The findings also revealed they also had a 12 percent lower risk of dying from cardiovascular issues during the study and a 14 percent lower risk of dying from cancer.

Whats more, these reductions in risk increased the more people exercised.

DON'T MISSHeart attack: Tasting this peculiar taste in your mouth could be an early warning sign[INSIGHT]Vitamin D deficiency symptoms: Feeling this in your fingers is an early warning sign[INSIGHT]How to get rid of visceral fat: The supplement proven to help banish the harmful belly fat[TIPS]

People who got 60 to 149 minutes of light-to-moderate exercise per week had a 22 percent lower risk of early death than sedentary people, and those who got 150 to 299 minutes had a 31 percent reduced risk.

In addition, those who engaged in 300 to 449 minutes of light-to-moderate physical activity per week was linked to a three percent lower risk of dying during the study period.

Out of all of the exercises available, aerobic exercise comes out on top for its myriad health benefits.

One of the primary health benefits of doing aerobic exercise is it helps keep visceral fat at bay.

Visceral fat is a harmful form of belly fat that lies close to internal organs and can trigger a range of deadly mechanisms in the body.

Emphasising the effectiveness of aerobic activity to attack visceral fat, many studies have shown that aerobic exercise can help you lose visceral fat, even without dieting.

For example, an analysis of 15 studies in 852 people compared how well different types of exercise reduced visceral fat without dieting.

They found moderate and high-intensity aerobic exercises were most effective at reducing visceral fat without dieting.

Aerobic exercise generally refers to any activity that gets your heart pumping and makes you breath faster than you normally would when resting.

Walking, jogging, biking, dancing, and swimming are popular examples of aerobic activity.

Of course, it is also important to compliment an exercise regime with a healthy, balanced diet too.

The NHS advises eating a low-fat, high-fibre diet, which should include plenty of fresh fruit and vegetables (five portions a day) and whole grains.

Read this article:
How to live longer: Do this much exercise each week to increase your life expectancy - Express

About 250,000 Americans die a year as a direct result of sedentary lifestyles.

The larger share of these deaths is more directly attributable to the development ofcardiovascular diseases. Many Americans lack either the time or the funds to commit to a gym membership which means fighting chronic inactivity begins with affordable ways to maintain physical fitness.

Thankfully, a study published in the JAMA Network Open recently became the first to identify push-up capacity as a preemptive correlate of poor heart health.

More discreetly, the researchers from the Harvard T.H. Chan School of Public Healthposited that middle-aged men who can complete 40 push-ups or more in a single try evidence a reduced risk of developing deadly cardiovascular diseases compared to individuals who can complete no more than ten push-ups in a single try.

Our findings provide evidence that push-up capacity could be an easy, no-cost method to help assess cardiovascular disease risk in almost any setting. Surprisingly, push-up capacity was more strongly associated with cardiovascular disease risk than the results of submaximal treadmill tests, explained the studys first authorJustin Yang, occupational medicine resident in theDepartment of Environmental Healthat Harvard T.H. Chan School of Public Health.

Push-up capacity is a no-cost, fast, and simple measure that may be a useful and objective clinical assessment tool for evaluating functional capacity and cardiovascular disease risk

There are several aspects of physical fitness that can be instructive for subsequent heart disease outcomes.

Calisthenics and resistance training are great waysto decrease blood pressure and stress put upon the heart. When performed correctly habitually doing push-ups can achieve the aforementioned benefits and even provide a dependable measure of an individuals longevity.

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. Robust evidence indicates an association of increased physical fitness with a lower risk of CVD events and improved longevity; however, few have studied simple, low-cost measures of functional status, the authors wrote in the report.

In order to determine the most effective and affordable methods of maintaining fitness, the researchers beganby reviewing health data from 1,104 male firefighters recorded annually between the years of 2000 and 2010. The average age of the participants was 39 and the median body-mass-index was about 28.7

Each participant was instructed to perform as many push-ups as they could in a single-try. These trials persisted over the course of ten years.

By the end of the study period, 37 participants developed a heart disease related condition 36 of these firefighters were not able to complete 40 push-ups in the initial trial. Although the researchers additionally tested treadmill endurance no discernible association was established between these demonstrations and the development of cardiovascular diseases.

More trials need to be done to determine if these outcomes could be replicated in women, younger men, and subjects who are less active than the firefighters involved in the study.

To perform a proper push-up make sure that your hands are shoulder-width apart or wider, your elbows are at a 45-degree angle as you bend towards the ground, and that your fingers are spread, with your middle finger pointing towards 12 oclock.

Push-up capacity is a no-cost, fast, and simple measure that may be a useful and objective clinical assessment tool for evaluating functional capacity and cardiovascular disease risk.

The new study was co-authored by JustinYang,MD, Costas A.Christophi,PhD andAndreaFarioli,MD, PhD and can be read in full in the JAMA Network Open.

Read more here:
Doing this many push-ups reduces heart disease risk by 96% - Ladders

Many believe that marriage is the elixir for happiness. Marriage can certainly make one feel more secure, loved and less stressed, however, new research is flipping this theory on its head and reveals that those living the single life tend to live longer than their couple counterparts. The research states that being single does not make one sad and constantly hankering after love - on the contrary, it may be the key to a long and joyous life. How can being single make a person live longer?

Emma Morano is 117 years old and is the oldest living person on Earth.

The Italian woman, born in 1899, just celebrated her birthday and dished her secret to a longer life, being single.

Its no coincidence that Japan, which famously holds the world's highest life expectancy, is on course to becoming a super-solo society with 50 percent of people being single.

Similarly, Sweden, currently the worlds single living capital, also boasts one of the highest life expectancy rates in the world.

Turns out, science shows that being single offers a whole host of health benefits.

READ MORE: Vitamin D deficiency symptoms: Lacking in the sunshine vitamin could cause this condition

One theory as to why single people live longer is down to the fact that single people socialise more.

Figures from the American Bureau of Labour Statistics showed single people spent more time chatting to friends than married couples.

Single people spend an average of 12 minutes a day staying in touch with other people over calls and emails.

Bella DePaulo, social psychologist wrote for Psychology Today said: These findings debunk the myth of the isolated single person.

"Singles spend more time in touch with other people, both in person and through other media.

Socialising and feeling a part of the community has been proven to increase life expectancy.

DONT MISS

Single people also tend to be slimmer and with weight directly linked to potentially life-threatening conditions and diseases, singles therefore tend to be healthier, according to a study published in the Journal of Family issued in 2015.

Experts found that single adults, no matter their sexual orientation, have a lower body weight.

In fact, the research determined that most single people have a lower body mass index.

The Western Washington University study looked at 20 years of data of more than 3,000 participants and found that people living with a partner tend to have a higher BMI, putting them at risk of potentially serious health conditions.

A survey by Amerisleep found that single people get the most sleep compared to those in a relationship.

It was recently reported that getting a good nights sleep was more important than sex when it comes to living well.

The survey found that single people get an average of 7.13 hours a night of sleep, however, those in a relationship slept for 7.07 and those married slept on average for only 6.71 hours.

Getting a good night's sleep is integral for overall health.

According to several scientific papers, if a person is happy being on their own and comfortable in their own skin, solitude can be an extremely positive thing.

Solitude, without loneliness, could increase productivity, spark creativity and has been shown to improve overall happiness and satisfaction across several aspects of life and it helps to reduce stress.

Research published in the Personality and Social Psychology Bulletin has linked solitude to everything from heightened sense of freedom to closer friendships.

Spending time alone gives one the time needed to rejuvenate and re-energise and allows the opportunity for personal reflection, getting to know oneself and to build self-resilience without relying on others.

Read the rest here:
How to live longer: Having this kind of relationship status could increase life expectancy - Express

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH) (NASDAQ: RCEL), a global regenerative medicine company, announced that management will present at the Cowen 40th Annual Health Care Conference in Boston. The presentation is being made on 4 March 2020 from 9:20 a.m. to 9:50 a.m. EST at the Boston Marriott Copley Place hotel. Interested parties may access a webcast of the presentation on the Investors section of the companys website at: https://www.avitamedical.com/investors.

Authorised for release by the Chief Financial Officer of Avita Medical Limited.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

More here:
AVITA Medical to Present at the Cowen 40th Annual Health Care Conference - Business Wire

Research into alternative stem cell sources has identified urine derived renal progenitor cells (UdRPCs) as a possible option for use in regenerative kidney therapies in the future.

Scientists have demonstrated their protocol for the reproducible isolation of kidney stem cells from human urine. These urine derived renal progenitor cells (UdRPCs) could be used to provide easier access to stem cells for regenerative kidney therapies and modelling diseases for R&D.

A shortage of donor organs and the risks and pain associated with bone marrow stem cell extractions and third trimester amniotic fluid collection have encouraged researchers to find alternative sources of stem cells. According to scientists, several laboratories have indicated urine could be an alternative source, at least for kidney stem cells, so the researchers from Heinrich Heine University-Duesseldorf (HHU) Germany,set out to complete a comprehensive molecular and cellular analysis of these cells.

UdRPCs should be considered as the choice of renal stem cells for facilitating the study of nephrogenesis, nephrotoxicity, disease modelling and drug development

Their study, published in Scientific Reports, revealed that UdRPCs isolated from ten individuals express both markers typically seen in bone marrow-derived mesenchymal stem cells (MSCs) and renal stem cells. The renal stem cell markers, according to the paper, allow UdRPCs to be differentiated into cell types present in the kidney, eg, podocytes and the proximal and distal tubules. The study also showed that these progenitor cells have similar properties to amniotic fluid-derived stem cells (AFCs).

Wasco Wruck, bioinformatician and co-author of the study, said: It is amazing that these valuable cells can be isolated from urine and comparing all the genes expressed in UdRPCs with that derived from kidney biopies we could confirm their renal and renal progenitor cell properties and origin.

According to Martina Bohndorf, a study co-author, UdRPCs can also be easily and efficiently reprogrammed into induced pluripotent stem cells using a non-viral integration-free and safe method.

Dr James Adjaye, study senior author and professor at the Institute for Stem Cell Research and Regenerative Medicine (ISRM) in the medical faculty of HHU, revealed that one of the most promising options in the near future is the use of transplantable renal stem cells (UdRPCs) for treatment of kidney diseases as a complementary option to kidney organs. He concluded that human UdRPCs should be considered as the choice of renal stem cells for facilitating the study of nephrogenesis, nephrotoxicity, disease modelling and drug development.

Original post:
Kidney stem cells isolated from urine could be regenerative therapies - Drug Target Review

CLEARWATER, Fla., Feb. 4, 2020 /PRNewswire/ --Florida Spine Institute (FSI)is the leading, and one of the most trusted, medical facilities specializing in pain management, neurology, surgery, physical medicine and rehabilitationin Tampa Bay. FSI offers a comprehensive wellness program with a multi-disciplinary spine care team, and board-certified diagnostic, medical, and surgical specialists that provide the most advanced care available. All patient consultations and most treatments are done on a single campus.

The state-of-the-art treatment modalities offered range from physical therapy and a variety of injections to procedures including radiofrequency ablation, spinal cord stimulation implants, toKetamine treatmentsand regenerative medicinesuch as stem cell treatments. Each patient's treatment is customized for the best results.

The Florida Spine Institute has a team of elite spine, neuro, and orthopedic surgeonswho combine surgical skills with experience for the most accurate and effective treatment. Our focus is on minimally invasive spine surgical techniques, motion preservation surgery, cervical and lumbar disc replacement surgery, as well as disc restoration.

FSI offers physical medicine and rehabilitation, a branch of medicine emphasizing the prevention, diagnosis, and treatment of nerve, muscle, bone and brain disorders. The Florida Spine Institute also has a friendly and relaxed in-house MRI imaging center, saving our patients valuable time to access this sophisticated procedure.

Neurologytreats disorders of the nervous system which include the brain and spinal cord, and the peripheral nervous system. Our staff neurologistis board certified by the American Board of Psychiatry & Neurology, the American Board of Electrodiagnostic Medicine, and the American Academy of Balance Medicine. He specializes in the treatment of headache, stroke, and epilepsy.

Botox injections, an FDA-approved treatment, has been safely used for treating various medical conditions since 1989, including muscle spasms, myofascial pain, headache, and back and neck pain. Our physicians can use Botox injections in a safe and effective manner to help ease your pain.

A relatively new cutting-edge treatment, Radiofrequency Ablation (RFA), is often favored over laser spine surgery because it utilizes smaller needles, so it is less invasive and is covered by insurance. RFA is used to treat not only neck and back pain, but also hip and knee pain.

IV Ketamine Infusion Therapy is the latest breakthrough treatment that is producing extraordinary results. Ketamine blocks receptors in the brain that, when overstimulated, are responsible for releasing chemicals that cause inflammation of the nervous system. IV Ketamine treatment has been found to be very effective in treating Depression, Pain, CRPS, PTSD, Fibromyalgia, Lyme Disease and more with excellent results.

Regenerative medicine is a game-changing area of medicine with the potential to heal damaged tissues and organs, offering solutions and hope for people who have conditions that might otherwise be thought to be beyond repair. The Florida Spine Institute offers cutting-edge regenerative medicine therapies that can help you feel better. From stem cell therapy to amniotic tissue treatments, we have a solution that is customized for you.

For more information, please visit http://www.floridaspineinstitute.comor call 727-797-7463

If you have questions regarding treatments with IV Ketamine, please visit http://www.ivketamine.comor call 727-KETAMINE or 727-538-2646.

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-florida-spine-institute-combines-excellence-and-compassion-in-pain-management-neurology-surgery-rehabilitation-physical-and-regenerative-medicine-300998791.html

SOURCE Florida Spine Institute

Go here to read the rest:
The Florida Spine Institute combines excellence and compassion in pain management, neurology, surgery, rehabilitation, physical and regenerative...

The Global Stem Cells Group (GSCG) is set to sponsor the XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad (World Conference of Anti-Aging and Longevity Medicine) to be held in Mexico City, Mexico on February 16-18, 2020.

The medical congress is expected to attract over 450 physicians and researchers from across the world interested in anti-aging and longevity practices and medical innovations. Over 30 speakers are slated to share information with attendees on a wide range of topics on how to lead a long, healthy life and improve longevity.

The GSCG is set to share a number of its latest innovations with congress attendees, including its newly released GCell technology device. This cutting-edge tool utilizes micrograft technology to harness the natural and powerful restorative capabilities of adipose tissues. Because it is FDA compliant, the device allows physicians across the globe to continue practicing adult stem cells-based procedures.

Additional benefits of GCell technology include shorter treatment times, delivering in-office treatments in around 30 minutes with local anesthesia, as well as less fat collection compared to existing treatments (15 mL versus 50 mL). GCell technology holds exciting implications across a range of medical specialties, including orthopedics, dermatology, cosmetic gynecology, aesthetics, and hair loss.

In addition to its GCell technology, the GSCG will also feature its newest line of stem cells products derived from first-tissue exosomes. Cellgenic Flow Exosomes utilizes the latest science and research available in cellular therapies to deliver a non-surgical approach to creating regenerative responses in a broad range of treatments. The product utilizes exosomes, which replicate the signals given out by stem cells, versus actual stem cells. Exosomes play a pivotal role in cell-to-cell communication and are involved in a wide range of physiological processes. These particles transfer critical bioactive molecules such as proteins, mRNA, and miRNA between cells and regulate gene expression in recipient cells.

The XI Congreso Mundial de Medicina Antienvejecimiento y Longevidad is one of the worlds premier events connecting physicians and researchers with todays most innovative treatments and technologies utilizing regenerative medicine, said Benito Novas, CEO of the GSCG. As a worldwide leader in training, education, and innovative products in the field of regenerative medicine, the GSCG is pleased to sponsor this congress and share its exciting new portfolio of products with physicians from across the world.

To learn more about the Global Stem Cells Group and all of the groups latest news and innovations, visit http://www.stemcellsgroup.com/

About Global Stem Cells Group

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCGs affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

See the article here:
Mexico City Medical Congress to Showcase the Global Stem Cells Group's Latest Innovations - PRUnderground

With promising results on its first rheumatological protein therapies, Dianomi is strategically expanding upon its core technology to deliver next-generation nucleic acid therapies

MADISON, Wis., Feb. 11, 2020 /PRNewswire/ --Dianomi Therapeutics Inc. today announced that it has licensed a second suite of intellectual property (IP) from the Wisconsin Alumni Research Foundation (WARF), expanding the use of its Mineral Coated Microparticle (MCM) technology into nucleic acid therapy.

Dianomi's core MCM technology mimics the natural, inherent properties of mineralized tissues to stabilize and control the release of active drug molecules and improve their therapeutic function, thus addressing common limitations of artificial polymer-based drug delivery systems. The newly acquired IP covers compositions and methods for delivering nucleic acid-based therapies and has broad utility across nucleic acid fields, including DNA, mRNA and RNAi applications.

Developed at the University of WisconsinMadison by William Murphy, Ph.D., a UW-Madison professor of biomedical engineering and orthopedics and rehabilitation, the MCM technology in combination with nucleic acids has demonstrated favorable results, both in vitro and in vivo. In early animal studies, results of mRNA delivery indicated enhanced transfection and localized sequestration of the gene product, promising a potentially potent and sustained therapeutic effect.

"Dianomi has demonstrated success in developing and optimizing MCM delivery for biologics and other small molecules," said Murphy, co-founder and chief scientific officer of Dianomi. "I look forward to Dianomi's expansion into the area of nucleic acid therapy, building upon the early results of our nucleic acid delivery in regenerative medicine applications."

The newly licensed IP includes issued U.S. patents as well as pending U.S. and international patent applications.Dianomi retains exclusive, global rights to pursue nucleic acid therapeutics independently and to build out its commercialization and development programs with other institutions and therapeutic entities.

"This new suite of intellectual property expands the capability of Dianomi's core technology into new indications and markets having significant commercial and clinical interest," said Martin Ostrowski, chief operations officer and general counsel of Dianomi. "We're thrilled to strengthen our relationship with WARF and continue developing the platform applicability of our technological and clinical programs to improve patient care."

Dianomi's first product is a tailored interleukin-1 receptor antagonist (IL-1Ra) for osteoarthritis, which utilizes Dianomi's MCM technology to provide sustained drug delivery. Dianomi intends to develop its own internal candidates while pursuing collaborative opportunities in a number of clinical indications, including cardiovascular, rheumatological, oncology, vaccines, regenerative medicine, neuromuscular and spinal degeneration, and general health and wellbeing.

About Dianomi

Dianomi Therapeutics is a biopharmaceutical company focused on optimizing the therapeutic profile of biologics, small molecules and nucleic acids to improve patient dosing, safety and efficacy. The company is advancing a pipeline of next-generation treatments for rheumatological disease states, initially targeting osteoarthritis and pain. The company's proprietary Mineral Coated Microparticle (MCM) technology mimics the ability of human bones and teeth to store and protect biologics, and provides greatly improved, sustained delivery of active biologics and other molecules. For more information on the company, please visit http://www.dianomitx.com.

About WARF

The Wisconsin Alumni Research Foundation (WARF) helps steward the cycle of research, discovery, commercialization and investment for the University of WisconsinMadison. Founded in 1925 as an independent, nonprofit foundation, WARF manages more than 2,000 patents and an investment portfolio of $2.7 billion as it funds university research, obtains patents for campus discoveries and licenses inventions to industry. For more information, visitwarf.organd viewWARF's Cycle of Innovation.

Media Contacts:

Dianomi Therapeutics

Joleen Rau Rau Communications 234030@email4pr.com(608) 209-0792

Wisconsin Alumni Research Foundation (WARF)

Jeanan Yasiri Moe Director of Strategic Communications (608) 960-9892

View original content:http://www.prnewswire.com/news-releases/dianomi-therapeutics-exclusively-licenses-nucleic-acid-technologies-from-the-wisconsin-alumni-research-foundation-warf-301002482.html

SOURCE Dianomi Therapeutics

Link:
Dianomi Therapeutics Exclusively Licenses Nucleic Acid Technologies from the Wisconsin Alumni Research Foundation (WARF) - Yahoo Finance

Indiana University has appointed Simran Trana as the university's first associate vice president of its Innovation and Commercialization Office.

The ICO identifies, protects and commercializes technology that comes from discoveries and innovations born from IU research. In recent years, under the umbrella of IU's Office of the Vice President for Research, the ICO has restructured to better serve IU inventors and those seeking to partner in bringing IU innovations to the public.

The new position of associate vice president reflects the university's increased focus on facilitating faculty innovation and the translation of innovations into the marketplace to serve the public. Among Trana's responsibilities will be enhancing strategic alliances with private- and public-sector partners and expanding the commercialization of IU discoveries and inventions, ensuring a service-oriented gateway for all members of the IU community seeking assistance with innovation and entrepreneurship.

Trana began her new IU role on Feb. 10.

"Having success in both industry and higher education, Simran brings the right mix of skills and experience to work with IU inventors and industry partners to shorten the time between discovery and the marketplace," said Fred H. Cate, IU vice president for research. "I am delighted that we will have the benefit of Simran's leadership to enhance delivery of the positive outcomes of IU research to Hoosiers and beyond."

Trana has 15 years of experience in product and business development, licensing and venture creation. She spent the past 10 years with Dow AgroSciences, now called Corteva Agriscience, the Agriculture Division of DowDuPont. Trana held multiple roles during this time, managing strategic research collaborations, technology licensing, intellectual property and portfolio development, new product launches, and licensing and corporate development. From 2001 to 2008, she served as director of technology commercialization for the Purdue Research Foundation, which manages and licenses intellectual property for Purdue University.

"Indiana University researchers and entrepreneurs have a long history of driving scientific innovation that impacts global progress and plays a key role in enhancing the well-being of Indiana residents and the Indiana economy," Trana said. "Knowing well that lives have and will be saved, or drastically improved, through access to new IU inventions or treatments, I am eager to get started."

Trana holds a master's degree in plant genetics from Punjab Agricultural University and a master of business administration from University of Ottawa.

She was selected for the new role at IU following a nationwide search involving university leaders:

The committee also included IU faculty inventors:

The Indiana University Innovation and Commercialization Office is tasked with the protection and commercialization of technology emanating from innovations by IU researchers. Since 1997, IU research has generated almost 3,200 inventions resulting in more than 4,800 global patent applications. These discoveries have generated more than $145 million in licensing and royalty income, including more than $115 million in funding for IU departments, labs and inventors.

Indiana University's world-class researchers have driven innovation and creative initiatives that matter for 200 years. From curing testicular cancer to collaborating with NASA to search for life on Mars, IU has earned its reputation as a world-class research institution. Supported by $680 million in 2019 from our partners, IU researchers are building collaborations and uncovering new solutions that improve lives in Indiana and around the globe.

Nicole Wilkins is executive director of research communications in the Office of the Vice President for Research.

More here:
Simran Trana appointed associate vice president of Innovation and Commercialization Office - IU Newsroom

MEDIA CONTACT

Available for logged-in reporters only

Newswise A UCLA-led study reveals a new role for a gene thats associated with autism spectrum disorder, intellectual disability and language impairment.

The gene, Foxp1, has previously been studied for its function in the neurons of the developing brain. But the new study reveals that its also important in a group of brain stem cells the precursors to mature neurons.

This discovery really broadens the scope of where we think Foxp1 is important, said Bennett Novitch, a member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLAand the senior author of the paper. And this gives us an expanded way of thinking about how its mutation affects patients.

Mutations in Foxp1 were first identified in patients with autism and language impairments more than a decade ago. During embryonic development, the protein plays a broad role in controlling the activity of many other genes related to blood, lung, heart, brain and spinal cord development. To study how Foxp1 mutations might cause autism, researchers have typically analyzed its role in the brains neurons.

Almost all of the attention has been placed on the expression of Foxp1 in neurons that are already formed, said Novitch, a UCLA professor of neurobiology who holds the Ethel Scheibel Chair in Neuroscience.

In the new study published in Cell Reports, he and his colleagues monitored levels of Foxp1 in the brains of developing mouse embryos. They found that, in normally developing animals, the gene was active far earlier than previous studies have indicated during the period when neural stem cells known as apical radial glia were just beginning to expand in numbers and generate a subset of brain cells found deep within the developing brain.

When mice lacked Foxp1, however, there were fewer apical radial glia at early stages of brain development, as well as fewer of the deep brain cells they normally produce. When levels of Foxp1 were above normal, the researchers observed more apical radial glia and an excess of those deep brain cells that appear early in development.In addition, continued high levels of Foxp1 at later stages of embryonic development led to unusual patterns of apical radial glia production of deep-layer neurons even after the mice were born.

What we saw was that both too much and too little Foxp1 affects the ability of neural stem cells to replicate and form certain neurons in a specific sequence in mice, Novitch said. And this fits with the structural and behavioral abnormalities that have been seen in human patients.

Some people, he explained, have mutations in the Foxp1 gene that blunt the activity of the Foxp1 protein, while others have mutations that change the proteins structure or make it hyperactive.

The team also found intriguing hints that Foxp1 might be important for a property specific to the developing human brain.The researchers also examined human brain tissue and discovered that Foxp1 is present not only in apical radial glia, as was seen in mice, but also in a second group of neuralstem cells called basal radial glia.

Basal radial glia are abundant in the developinghuman brain, but absent or sparse in the brains of many other animals, including mice.However, when Novitchs team elevated Foxp1 function in the brains of mice, cells resembling basal radial glia were formed. Scientists have hypothesized that basal radial glia also are connected to the size of the human brain cortex: Their presence in large quantities in the human brain may help explain why it is disproportionately larger than those of other animals.

Novitch said that although the new research does not have any immediate implications for the treatment of autism or other diseases associated with Foxp1 mutations, it does help researchers understand the underlying causes of those disorders.

In future research, Novitch and his colleagues are planning to study what genes Foxp1 regulates in apical radial glia and basal radial glia, and what roles those genes play in the developing brain.

The studys first author is Caroline Alayne Pearson, a UCLA assistant project scientist. Other authors are from the University of Texas at Austin, the University of Alabama at Birmingham and the University of Puerto Rico.

The study was funded by the National Institutes of Health, the California Institute for Regenerative Medicine, the Cancer Prevention and Research Institute of Texas, the University of Texas at Austins Marie Betzner Morrow Centennial Endowment and the UCLA Broad Stem Cell Research Centers Research Award Program, including support from the Binder Foundation.

SEE ORIGINAL STUDY

Read more:
Gene associated with autism also controls growth of the embryonic brain - Newswise

Paul Mischel (right) is one of six researchers suing the Ludwig Institute for Cancer Research for tapering down its funding.

By Michael PriceFeb. 7, 2020 , 7:10 PM

Alleging that a leading cancer funder is slashing their support in an unethical and reckless way, six prominent cancer researchers at the University of California, San Diego (UCSD), have filed a lawsuit to compel it to continue its current level of support. The suit, filed quietly in November 2019 and amended last week, contends that the Ludwig Institute for Cancer Research(LICR) is gradually drawing down its funding for cancer prevention and treatment research to the six plaintiffs, in order to close its 29-year-old San Diego branch by 2023.

In a statement, LIRC confirmed it is winding down the San Diego branchbut stressed that, [i]n implementing this decision, the Ludwig Institute is honoring its contractual obligations. LICR also said it plans to respond to the lawsuits specific allegations in due course.

The six plaintiffs, Don Cleveland, Arshad Desai, Richard Kolodner, Paul Mischel, Karen Oegema, and Bing Ren, primarily study tumor biology and cancer genomics, though some work more broadly, including Cleveland, who is also known for research on Huntingtondisease. In addition to funding from LICR, they receive substantial support from the National Institutes of Health (NIH), the California Institute for Regenerative Medicine, the Breakthrough Prize, and other sources.

LICR, a nonprofit organization based in New York City and Zurich, nowoversees nine research centers at universities and research hospitals around the world, including seven in the United States. According to figures from the institute, it has committed some $2.5 billion to cancer research since its founding in 1971. Scientists working at its research centers are co-employed as faculty members of LICR and their host institutions, with LICR partially funding the scientists work. In return, LICR earns revenue from patents and licensing agreements related to the scientists work. The San Diego branch is hosted by UCSD. According to figures cited in the lawsuit, between 2013 and 2018, LICR provided the university between $11.5 million and $13.2 million annually, including more than $3 million annually for research activities.

Jeremy Rich, a neuro-oncologist at the UCSD School of Medicine who has collaborated with LICR scientists, says the plaintiffs are the victims of a relationship between UCSD and LICR that has been in a downward spiral for years. The university, he says, doesnt see LICRas one of its own. The deteriorating relationship has fomented doubt about where the scientists loyalties lie, he says. Unfortunately for the investigators, theyre caught between two institutions, he says. It is a tragic thing for cancer research. Our enemies are not one another, but cancer.

The lawsuit, filed by six of the seven principal investigators at the branch, says that the LICR board of directors told the plaintiffs in a May 2018 meeting that it planned to close the branch at the end of 2023, when the researchers contracts end. The complaint saysLICR informed the researchers it would impose a substantially reduced level of funding beginning in 2019 and provide a tapering research budget while the scientists transitioned their research programs elsewhere. Since 2016, LICR has closed branches in Brussels;Melbourne, Australia;So Paulo;Stockholm;and Uppsala, Sweden.

By tapering their funding, the plaintiffs argue, LICR is breaching its agreement to provide future financial support for continuous, active conduct of medical research towards a cure for cancer at UCSD. The plaintiffs ask the court to make LICR continue to fundtheir research programs through 2023 at levels comparable to previous years. They also seek rights to the intellectual property they have generated, which would prevent LICR from filing patents on their work.

In addition, the scientists accuse LICR leadership of damaging their professional reputations. LICR, the lawsuit says, asserted in reckless, unjustified and unsupported public statementsthat the Plaintiffs were not performing cancer research at a level on par with their seniority and the funding.The lawsuit does not detail those statements, however.

Webster Cavenee, a former director of the LICR San Diego branch and current director of an LICR research program at UCSD for central nervous system cancers, declined to discuss the details of the lawsuit, but told ScienceInsider, the San Diego branch was measurably the most recognized and honored branch in the institute.

These scientists are renowned, says David Brenner, UCSD vice chancellor for health sciences, in a statement. They have won numerous awards and garnered significant acclaim from both their peers and the world at large. They have made major contributions in all aspects of cancer science and medicine, from basic research to clinical care, and their work is not yet done.

A UCSD spokesperson confirmed that because each of the researchers is a faculty member, termination of their Ludwig support does not terminate their UC San Diego faculty status, and they will continue to occupy the same space at university faculty. Its unclear how a closing of the branch and tapering of LICR funding might affect funding from NIH or other agencies.

Read the original post:
Major cancer institute sued by its own researchers over 'tapering' funding - Science Magazine

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company recently held a high level meeting with the U.S. Food and Drug Administration (FDA) to discuss potential NurOwn regulatory pathways for approval in ALS. Repeated intrathecal administration of NurOwn (autologous MSC-NTF cells) is currently being evaluated in a fully enrolled Phase 3 pivotal trial in ALS (NCT03280056).

In the planned meeting with senior Center for Biologics Evaluation and Research (CBER) leadership and several leading U.S. ALS experts, the FDA confirmed that the fully enrolled Phase 3 ALS trial is collecting relevant data critical to the assessment of NurOwn efficacy. The FDA indicated that they will look at the "totality of the evidence" in the expected Phase 3 clinical trial data. Furthermore, based on their detailed data assessment, they are committed to work collaboratively with BrainStorm to identify a regulatory pathway forward, including opportunities to expedite statistical review of data from the Phase 3 trial.

Both the FDA and BrainStorm acknowledged the urgent unmet need and the shared goal of moving much needed therapies for ALS forward as quickly as possible.

This is a key turning point in ourworktowardprovidingALSpatientswith a potential new therapy,said ChaimLebovits, President and CEO ofBrainStorm. We commend the FDA foritscommitmentto the ALS communityandtofacilitating the development, and we ultimately hope, the approvalofNurOwn.The entire BrainStorm team is grateful for the ongoing and conscientious collaboration in the quest to beat ALS.

Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, stated, The entire team at BrainStorm has collectively worked to ensure that we conduct the finest, science-based clinical trials. We had the opportunity to communicate with Senior Leadership at the FDA and discuss how we can work together to navigate the approval process forward along a novel pathway. We appreciate their willingness and receptiveness to consider innovative approaches as we all seek to better serve the urgent unmet medical needs of the ALS community.

Brian Wallach, Co-Founder of I AM ALS stated: There is nothing more important to those living with ALS than having access to therapies that effectively combat this fatal disease. We have been working with BrainStorm for months now because we believe that NurOwn is a potentially transformative therapy in this fight. We were privileged to represent the patient voice at this meeting and are truly grateful to the company and the FDA for this critical agreement. This is a truly important moment of hope and we look forward to seeing both the Phase III data and the hopeful approval of NurOwn as soon as is possible.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. BrainStorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Story continues

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Or

Katie Gallagher | Account Director, PR and MarketingLaVoieHealthScience Strategic CommunicationsO: 617-374-8800 x109M: 617-792-3937kgallagher@lavoiehealthscience.com

View original post here:
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn Regulatory Pathway for Approval in ALS - Yahoo Finance